| Literature DB >> 32656473 |
Richard A Pizzo1, Tyler Hoskins1, Jay N Patel1, Justin M Miller1, David Goyette1, Christopher Mazzei1, James C Wittig1.
Abstract
The humerus is a common site of metastatic tumor involvement and pathologic fracture. Intramedullary nailing is a treatment option that offers the benefit of protecting a long segment of diseased bone, but it is not without complications. This study aims to examine the survival, functional outcomes, and complications of patients treated with cement-augmented unlocked intramedullary nailing for actual and impending pathologic fractures of the humeral shaft.Entities:
Year: 2020 PMID: 32656473 PMCID: PMC7322774 DOI: 10.5435/JAAOSGlobal-D-20-00090
Source DB: PubMed Journal: J Am Acad Orthop Surg Glob Res Rev ISSN: 2474-7661
Figure 1A, Radiograph of the humerus demonstrating lytic lesions of both the humeral shaft and proximal humerus with notable cortical compromise, resulting in nondisplaced pathologic fracture of the surgical neck. B, Intraoperative fluoroscopy demonstrating identification of the starting point for instrumenting the humerus. C, Intraoperative fluoroscopy depicting the use of a looped curet through the starting point in the humeral head to grossly debulk the tumor.
Figure 2A, Intraoperative fluoroscopy showing cement being injected into the distal humeral shaft. Arrow indicates the tip of the cement gun nozzle. B/C. Intraoperative fluoroscopy demonstrating the proximal (B) and distal (C) aspects of the final cemented intramedullary nailing construct.
Selected Patient Demographics
| Age, y, mean (SD) | 66.8 (12.1) |
| Sex, n (%) | |
| Male | 9 (52.9) |
| Female | 8 (47.1) |
| Fracture status, n (%) | |
| Fracture | 8 (47.1) |
| Impending | 9 (52.9) |
| Laterality, n (%) | |
| Left | 6 (35.3) |
| Right | 11 (64.7) |
| Lesion type, n (%) | |
| Primary | 5 (29.4) |
| Metastatic | 12 (70.6) |
| Pathology, n (%) | |
| Myeloma | 5 (29.3) |
| Breast adenocarcinoma | 3 (17.6) |
| Lung adenocarcinoma | 2 (11.8) |
| Renal cell carcinoma | 2 (11.8) |
| Lymphoma | 1 (5.9) |
| Thyroid adenocarcinoma | 1 (5.9) |
| Prostate adenocarcinoma | 1 (5.9) |
| Pharyngeal carcinoma | 1 (5.9) |
| Vulvar squamous cell carcinoma | 1 (5.9) |
Figure 3The mean MSTS score of patients with pathologic fractures and impending fractures before surgery versus at final follow-up. MSTS = Musculoskeletal Tumor Society